866-997-4948(US-Canada Toll Free)

Brain Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 107 Pages

Brain Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Brain Cancer - Pipeline Review, H2 2014, provides an overview of the Brain Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Brain Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Brain Cancer - Overview 9
Pipeline Products for Brain Cancer - Comparative Analysis 10
Brain Cancer - Therapeutics under Development by Companies 11
Brain Cancer - Therapeutics under Investigation by Universities/Institutes 13
Brain Cancer - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Brain Cancer - Products under Development by Companies 16
Brain Cancer - Products under Investigation by Universities/Institutes 17
Brain Cancer - Companies Involved in Therapeutics Development 18
Neuralstem, Inc. 18
Bionomics Limited 19
Critical Outcome Technologies Inc. 20
Prana Biotechnology Limited 21
e-Therapeutics plc 22
AngioChem Inc. 23
Merrimack Pharmaceuticals, Inc. 24
Stemline Therapeutics, Inc. 25
Kinex Pharmaceuticals, LLC 26
Nuvilex, Inc. 27
TAU Therapeutics, LLC 28
CureFAKtor Pharmaceuticals. LLC 29
Arrien Pharmaceuticals, LLC 30
Oncology Research International Limited 31
Brain Cancer - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
pritumumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
dexanabinol - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MDNA-55 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KX-02 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
COTI-2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
irinotecan sucrosofate liposomal - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SL-302 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BNC-105 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ANG-1007 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
TTL-1177 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CFAK-C4 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NSI-566 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
KX-02 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CFAKY-15 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PBT-519 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ARN-7016 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Vaccine for Brain Cancer and Glioblastoma Multiforme - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
imipramine blue nanocarrier - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ORIL-007 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Methoxynaphthylfenoterol - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
SL-301 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Cannabidiol For Pancreatic Cancer And Brain Cancer - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule for Brain Cancer - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Brain Cancer - Recent Pipeline Updates 74
Brain Cancer - Dormant Projects 96
Brain Cancer - Discontinued Products 97
Brain Cancer - Product Development Milestones 98
Featured News & Press Releases 98
Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis 98
May 15, 2014: Diffusion Pharmaceuticals Clinical Trial of TSC in Brain Cancer Reaches One Year Interim Endpoint 99
May 08, 2014: e-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial 99
Apr 08, 2014: ZIOPHARM Presents Preclinical Data at AACR Annual Meeting Supporting Controlled DNA-based IL-12 Therapy for Brain Cancer 100
Mar 07, 2014: NW Bio Receives Recommendation to Continue with Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Boards Safety Review 101
Jan 07, 2014: e-Therapeutics provides update on ETS2101 phase I trial in brain cancer 101
Dec 16, 2013: Positive Phase 2 Results from Agenus Brain Cancer Vaccine Published in Neuro-Oncology 102
Nov 25, 2013: NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-113 103
Oct 21, 2013: Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate, ANG1005, in Primary Brain Cancer 103
Sep 26, 2013: to-BBB Presents Clinical Data on Lead Product 2B3-101 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107

List of Tables
Number of Products under Development for Brain Cancer, H2 2014 9
Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Brain Cancer - Pipeline by Neuralstem, Inc., H2 2014 18
Brain Cancer - Pipeline by Bionomics Limited, H2 2014 19
Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 20
Brain Cancer - Pipeline by Prana Biotechnology Limited, H2 2014 21
Brain Cancer - Pipeline by e-Therapeutics plc, H2 2014 22
Brain Cancer - Pipeline by AngioChem Inc., H2 2014 23
Brain Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 24
Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2014 25
Brain Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 26
Brain Cancer - Pipeline by Nuvilex, Inc., H2 2014 27
Brain Cancer - Pipeline by TAU Therapeutics, LLC, H2 2014 28
Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H2 2014 29
Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 30
Brain Cancer - Pipeline by Oncology Research International Limited, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Brain Cancer Therapeutics - Recent Pipeline Updates, H2 2014 74
Brain Cancer - Dormant Projects, H2 2014 96
Brain Cancer - Discontinued Products, H2 2014 97

List of Figures
Number of Products under Development for Brain Cancer, H2 2014 9
Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Products, H2 2014 15
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Top 10 Target, H2 2014 33
Number of Products by Stage and Top 10 Target, H2 2014 34
Number of Products by Top 10 Mechanism of Action, H2 2014 36
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 37
Number of Products by Top 10 Route of Administration, H2 2014 39
Number of Products by Stage and Top 10 Route of Administration, H2 2014 40
Number of Products by Top 10 Molecule Type, H2 2014 41
Number of Products by Stage and Top 10 Molecule Type, H2 2014 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *